Vaccine with beta-glucan for high-risk neuroblastoma
Part of Cancer clinical trials.
This trial tests a vaccine combined with a substance called beta-glucan to help the immune system recognize and fight neuroblastoma cells. It is for children who have already completed treatment for high-risk neuroblastoma and are now in remission.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must have been diagnosed with high-risk neuroblastoma
- Your child must be in complete remission (no signs of cancer)
- Your child must have finished their last cancer treatment at least 3 weeks ago but less than 6 months ago
- Your child's blood counts and organ function must be at acceptable levels
- Your child must not have had an allergic reaction to certain vaccine ingredients or beta-glucan
- You and your child must be willing to follow the study schedule and procedures
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a vaccine, combined with two other immune-boosting drugs (β-glucan and GM-CSF), to see if it can help keep neuroblastoma from coming back. It's for people who have already completed standard treatment and are in remission.
This study tests a new combination of drugs (a GSL synthetase inhibitor, GM-CSF, and possibly an immune checkpoint inhibitor) for people with high-risk neuroblastoma that has already been treated. It aims to see if this combination can help shrink tumors or slow the disease.
This trial tests a combination of chemotherapy and immunotherapy as a first treatment for children and young adults with high-risk neuroblastoma. The goal is to see if this approach can improve outcomes.
This Phase 3 study tests whether adding either a targeted drug (lorlatinib) or a radioactive treatment (131I-MIBG) to intensive chemotherapy improves outcomes for children with high-risk neuroblastoma. It may help by aiming at tumor cells more directly alongside standard treatment.
This trial tests adding the antibody dinutuximab-beta to standard chemotherapy for children and young adults with newly diagnosed high-risk neuroblastoma. The goal is to see if this combination helps the immune system fight the cancer better.
This trial tests adding a targeted drug called dinutuximab to standard chemotherapy, surgery, and a stem cell transplant for children and young adults with a new diagnosis of high-risk neuroblastoma. The goal is to see if this combination helps more patients stay in remission.
Hear when a new Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.